首页 | 本学科首页   官方微博 | 高级检索  
     


Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
Affiliation:1. Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA;2. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, USA;3. Department of Pathology, School of Medicine, Yale University, New Haven, CT 06510, USA;4. Thoracic Oncology Program, Langone-Laura and Isaac Perlmutter Cancer Center, New York University, New York, NY 10016, USA;5. Experimental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA;6. Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA;7. Department of Plastic Surgery, Surgery Institute, Cleveland Clinic, Cleveland, OH 44195, USA;8. Thoracic Epigenetics Section, Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA;9. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Abstract:
><ol class=
  • Download : Download high-res image (251KB)
  • Download : Download full-size image
  • Keywords:small cell lung cancer  immune checkpoint blockade  pyrimidine metabolism  decitabine  5-azacytidine  tetrahydrouridine  chemotherapy resistance  radiation resistance  CP: Cancer
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号